Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Qian Zhao,Shan-Shan Xiong,Can Chen,Hong-Ping Zhu,Xin Xie,Cheng Peng,Gu He,Bo Han

DOI: https://doi.org/10.3389/fonc.2023.1259550

IF: 4.7

2023-08-25

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.972372.].

oncology

What problem does this paper attempt to address?

Corrigendum: Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells

Xu Wang,Renjie Hui,Yun Chen,Wentao Wang,Yujiao Chen,Xiaohai Gong,Jian Jin

DOI: https://doi.org/10.3389/fphar.2020.603491

IF: 5.6

2020-11-26

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2019.01434.].

pharmacology & pharmacy
Corrigendum to 'inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer' [ebiomedicine 31 (2018) 276-286].

Tao Zhang,Jingjie Li,Xiaojun Ma,Yang,Wei Sun,Wangrui Jin,Lei Wang,Yuan He,Feifei Yang,Zhengfang Yi,Yingqi Hua,Mingyao Liu,Yihua Chen,Zhengdong Cai

DOI: https://doi.org/10.1016/j.ebiom.2020.102629

IF: 11.205

2020-01-01

EBioMedicine

Abstract:The published version of this article contained an error in Fig. 2c and f, the corrected Fig. 2 is included below, the authors declare that the corrections do not change the results or conclusions of this paper and apologize for any inconvenience this may have caused.
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Corrigendum: Design, synthesis, and antitumor activity study of all-hydrocarbon-stapled B1-Leu peptides.

Zhen Su,Chao Liu,Wei Cong,Shipeng He,Li Su,Honggang Hu

DOI: https://doi.org/10.3389/fchem.2023.1285116

IF: 5.5

2023-01-01

Frontiers in Chemistry

Abstract:[This corrects the article DOI: 10.3389/fchem.2022.840131.].
Correction to "Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma"

Xiaopeng Peng,Ling Li,Jingxuan Chen,Yichang Ren,Jin Liu,Ziwen Yu,Hao Cao,Jianjun Chen

DOI: https://doi.org/10.1021/acs.jmedchem.4c02486

IF: 8.039

2024-10-20

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Oct 19. doi: 10.1021/acs.jmedchem.4c02486. Online ahead of print. NO

chemistry, medicinal
Correction to "Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity"

Elisa Giacomini,Angela Nebbioso,Alfonso Ciotta,Cristina Ianni,Federico Falchi,Marinella Roberti,Manlio Tolomeo,Stefania Grimaudo,Antonietta Di Cristina,Rosaria Maria Pipitone,Lucia Altucci,Maurizio Recanatini

DOI: https://doi.org/10.1021/acsmedchemlett.4c00301

2024-07-03

Abstract:[This corrects the article DOI: 10.1021/ml5000959.].
Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Yihui Zhou,Xiaomeng Gao,Yuan Meng,Bo Yang,Qiaojun He,Ji Cao

DOI: https://doi.org/10.3389/fphar.2021.785732

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.748852.].
Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Xiu-Ying He,Yang Xu,Qing-Jie Xia,Xiao-Ming Zhao,Shan Li,Xiao-Qiong He,Ru-Rong Wang,Ting-Hua Wang

DOI: https://doi.org/10.3389/fonc.2022.872110

IF: 4.7

2022-03-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.663262.].

oncology
Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Yi Qian,Meimei Zhao,Qinghua Han,Jingkang Wang,Lixi Liao,Heng Yang,Dan Liu,Pengfei Tu,Hong Liang,Kewu Zeng

DOI: https://doi.org/10.1016/j.apsb.2024.02.013

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.01.011.].
Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Xiaozhong Liao,Ying Gao,Jiahui Liu,Lan-Ting Tao,Dongmei Wang,Dan Xie,Sui‐Lin Mo

DOI: https://doi.org/10.3389/fonc.2021.670798

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.01756/full.].
Correction: Discovery of a (19)F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells.

Qiuyan Shi,Yu Li,Shaowei Bo,Xiaofei Li,Peng Zhao,Qi Liu,Zhigang Yang,Hengjiang Cong,Hexiang Deng,Mingnan Chen,Shizhen Chen,Xin Zhou,Hong Ding,Zhong-Xing Jiang

DOI: https://doi.org/10.1039/c6cc90215d

2016-01-01

Abstract:Correction for 'Discovery of a (19)F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells' by Qiuyan Shi et al., Chem. Commun., 2016, 52, 5136-5139.
Correction to “discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3”

Chuhui Huang,Si,Grace Lin,Anders Poulsen,Melgious Jin Yan Ang,Burton K. Chia,Sin Yin Chew,Zekui P. Kwek,John Liang Kuan Wee,Esther Ong,Priya Retna,Nithya Baburajendran,Rong Li,Weixuan Yu,Xiaoying Koh-Stenta,Anna Ngo,Sravanthy Manesh,Justina Fulwood,Ke Zhao,Hwa,Sugunavathi Sepramaniam,Xin Hui Chew,Nurul Dinie,May Ann Lee,Yun Shan Chew,Choon Bing Low,Vishal Pendharkar,Vithya Manoharan,Susmitha Vuddagiri,Kanda Sangthongpitag,Joma Joy,Alex Matter,Jeffrey Hill,Thomas H. Keller,Klement Foo

DOI: https://doi.org/10.1021/acsmedchemlett.9b00278

2019-01-01

ACS Medicinal Chemistry Letters

Abstract:[This corrects the article DOI: 10.1021/acsmedchemlett.9b00170.].
Corrigendum: Dihydrocapsaicin inhibits cell proliferation and metastasis in melanoma via down-regulating β-catenin pathway.

Shaomin Shi,Chongyang Li,Yanli Zhang,Chaowei Deng,Wei Liu,Juan Du,Qian Li,Yacong Ji,Leiyang Guo,Lichao Liu,Huanrong Hu,Yaling Liu,Hongjuan Cui

DOI: https://doi.org/10.3389/fonc.2022.1052365

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.648052.].
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Xing Bian,Xiaolin Wang,Qiuyan Zhang,Liying Ma,Guozhen Cao,Ao Xu,Jinhua Han,Jun Huang,Wenchu Lin

DOI: https://doi.org/10.3389/fonc.2023.1192526

IF: 4.7

2023-04-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.565820.].

oncology
Correction: O2-(6-Oxocyclohex-1-en-1-yl)methyl Diazen-1-ium-1,2-diolates: a New Class of Nitric Oxide Donors Activatable by GSH/GSTπ with Both Anti-Proliferative and Anti-Metastatic Activities Against Melanoma.

Chengfeng Bai,Rongfang Xue,Jianbing Wu,Lu Tian,Xiang Liu,Yun Huang,Yi Gong,Honghua Zhang,Yihua Zhang,Zhangjian Huang

DOI: https://doi.org/10.1039/d0cc90145h

IF: 4.9

2020-01-01

Chemical Communications

Abstract:Correction for 'O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma' by Chengfeng Bai et al., Chem. Commun., 2017, 53, 5059-5062.
Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Chunju Yang,Bang Li,Zongbo Feng,Huaxuan Li,Hong Yang,Zhenjiao Yang,Li Liu,Qiongyu Shi,Hong Wang,Zhong-Zhu Chen,Xun Huang,Junjian Wang,Yuanxiang Wang

DOI: https://doi.org/10.1021/acs.jmedchem.4c02417

IF: 8.039

2024-10-17

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Oct 15. doi: 10.1021/acs.jmedchem.4c02417. Online ahead of print. NO

chemistry, medicinal
Corrigendum: Anticancer applications of phytochemicals in gastric cancer: effects and molecular mechanism

Zhaofeng Liang,Yumeng Xu,Yue Zhang,Xinyi Zhang,Jiajia Song,Hui Qian,Jianhua Jin

DOI: https://doi.org/10.3389/fphar.2024.1405513

2024-08-19

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.1078090.].
Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1 H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

Nilesh Raghunath Khedkar,Milind Sindkhedkar,Alex Joseph

DOI: https://doi.org/10.1039/d4md90040e

2024-10-15

Abstract:[This corrects the article DOI: 10.1039/D4MD00055B.].
Author Correction: Pharmacophore Hybridisation and Nanoscale Assembly to Discover Self-Delivering Lysosomotropic New-Chemical Entities for Cancer Therapy

Zhao Ma,Jin Li,Kai Lin,Mythili Ramachandran,Dalin Zhang,Megan Showalter,Cristabelle De Souza,Aaron Lindstrom,Lucas N. Solano,Bei Jia,Shiro Urayama,Yuyou Duan,Oliver Fiehn,Tzu-yin Lin,Minyong Li,Yuanpei Li

DOI: https://doi.org/10.1038/s41467-021-22419-2

IF: 16.6

2021-01-01

Nature Communications

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-22419-2

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Corrigendum: Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells

Corrigendum to 'inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer' [ebiomedicine 31 (2018) 276-286].

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: Design, synthesis, and antitumor activity study of all-hydrocarbon-stapled B1-Leu peptides.

Correction to "Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma"

Correction to "Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity"

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Correction: Discovery of a (19)F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells.

Correction to “discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3”

Corrigendum: Dihydrocapsaicin inhibits cell proliferation and metastasis in melanoma via down-regulating β-catenin pathway.

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Correction: O2-(6-Oxocyclohex-1-en-1-yl)methyl Diazen-1-ium-1,2-diolates: a New Class of Nitric Oxide Donors Activatable by GSH/GSTπ with Both Anti-Proliferative and Anti-Metastatic Activities Against Melanoma.

Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Corrigendum: Anticancer applications of phytochemicals in gastric cancer: effects and molecular mechanism

Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1 H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

Author Correction: Pharmacophore Hybridisation and Nanoscale Assembly to Discover Self-Delivering Lysosomotropic New-Chemical Entities for Cancer Therapy